Cost-Effectiveness Analysis of <sup>177</sup> Lu-PSMA-617 Versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer from a U.S. Health Care Perspective
Kemal C. Gogebakan, Natalia Kunst, Alireza Ghodsi, Lukas Owens, Amir Iravani, Ruth Douglas Etzioni
原始摘要（英文原文）· Original abstract
Lu-PSMA-617 was not cost-effective compared with cabazitaxel in the base case analysis, it may achieve cost-effectiveness under more favorable assumptions of survival benefit or reduced cost per cycle. Probabilistic analyses further highlighted substantial uncertainty, with a low likelihood of cost-effectiveness.
Cost-Effectiveness Analysis of <sup>177</sup> Lu-PSMA-617 Versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer from a U.S. Health Care Perspective — 科研速览 Science Skim